Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
State Key Laboratory of Molecular Oncology, Key Laboratory of Cancer and Microbiome, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Br J Cancer. 2022 Nov;127(11):2052-2059. doi: 10.1038/s41416-022-01997-y. Epub 2022 Oct 7.
The treatment strategies for T1 oesophageal squamous cell carcinoma (ESCC) patients with or without lymph node metastasis (LNM) are different. Given the advantages of the minimally invasive, sensitive and real-time detection, liquid biopsy has become an important cancer diagnostic and prognostic tool.
MiRNA array and small-RNA sequencing were performed. Then, 222 formalin-fixed and paraffin-embedded tumour samples and 229 pretreatment serum samples from T1 ESCC patients were used to verify and evaluate the results.
We demonstrated that serum miR-20b-5p could predict LNM in T1 ESCC patients. The AUC for serum miR-20b-5p was higher (0.827) than those for lymphovascular invasion (LVI) (0.751, P = 0.2128), invasion depth (0.662, P = 0.0027) and tumour differentiation grade (0.634, P = 0.0019). A nomogram for predicting LNM with three independent significant predictors (miR-20b-5p, LVI and invasion depth) was constructed with a concordance index of 0.931. Serum miR-20b-5p was also significantly correlated with disease-free survival (P < 0.001). An algorithm of improved T1 ESCC treatment strategy after biopsy and/or after endoscopic resection based on serum miR-20b-5p level was constructed.
This study suggests that serum miR-20b-5p is a potential biomarker for predicting LNM and can be helpful for precise clinical decision-making strategies and improve treatment outcomes for T1 ESCC patients.
T1 食管鳞状细胞癌(ESCC)患者伴或不伴淋巴结转移(LNM)的治疗策略不同。鉴于液体活检具有微创、敏感和实时检测的优势,已成为一种重要的癌症诊断和预后工具。
进行 miRNA 阵列和小 RNA 测序。然后,使用 222 例 T1 ESCC 患者的福尔马林固定石蜡包埋肿瘤样本和 229 例治疗前血清样本进行验证和评估。
我们证明了血清 miR-20b-5p 可预测 T1 ESCC 患者的 LNM。血清 miR-20b-5p 的 AUC 高于淋巴血管侵犯(LVI)(0.751,P=0.2128)、浸润深度(0.662,P=0.0027)和肿瘤分化程度(0.634,P=0.0019)。构建了一个包含三个独立显著预测因子(miR-20b-5p、LVI 和浸润深度)的 LNM 预测列线图,其一致性指数为 0.931。血清 miR-20b-5p 与无病生存期显著相关(P<0.001)。基于血清 miR-20b-5p 水平构建了改进的活检后和/或内镜切除后 T1 ESCC 治疗策略的算法。
本研究表明,血清 miR-20b-5p 是预测 LNM 的潜在生物标志物,有助于制定精确的临床决策策略,改善 T1 ESCC 患者的治疗效果。